Matching articles for "Rytary"
Issue 1753 · April 27, 2026 Free
In Brief: New Warnings for Carbidopa/Levodopa Products

The FDA has required that the labels of all carbidopa/levodopa-containing products (Crexont, Dhivy, Duopa, Rytary, Sinemet, Sinemet CR, Stalevo, Vyalev) include a warning about the risk of vitamin B6…

Med Lett Drugs Ther. 2026 Apr 27; 68(1753):72 doi:10.58347/tml.2026.1753b
The FDA has required that the labels of all carbidopa/levodopa-containing products (Crexont, Dhivy, Duopa, Rytary, Sinemet, Sinemet CR, Stalevo, Vyalev) include a warning about the risk of vitamin B6 (pyridoxine) deficiency and vitamin B6 deficiency-related seizures associated with their use. The combination of carbidopa/levodopa is the most effective treatment for the motor symptoms of Parkinson's disease and recent evidence favors its early use.
Issue 1718 · December 23, 2024
Crexont — Extended-Release Carbidopa/Levodopa for Parkinson's Disease

The FDA has approved Crexont (Amneal), an extended-release capsule formulation of carbidopa/levodopa, for treatment of Parkinson's disease (PD), postencephalitic parkinsonism, and parkinsonism associated with…

Med Lett Drugs Ther. 2024 Dec 23; 66(1718):206-8 doi:10.58347/tml.2024.1718e
The FDA has approved Crexont (Amneal), an extended-release capsule formulation of carbidopa/levodopa, for treatment of Parkinson's disease (PD), postencephalitic parkinsonism, and parkinsonism associated with carbon monoxide or manganese intoxication. Crexont contains a combination of immediate-release carbidopa/levodopa granules and extended-release levodopa pellets. An extended-release carbidopa/levodopa oral capsule (Rytary) has been available from the same manufacturer for years; the patent for Rytary expires in 2025.
Issue 1618 · February 22, 2021
Drugs for Parkinson's Disease

The motor symptoms of Parkinson's disease (PD) are caused primarily by degeneration of dopaminergic neurons in the substantia nigra. The nonmotor symptoms of the disease are thought to be caused by…

Med Lett Drugs Ther. 2021 Feb 22; 63(1618):25-32
The motor symptoms of Parkinson's disease (PD) are caused primarily by degeneration of dopaminergic neurons in the substantia nigra. The nonmotor symptoms of the disease are thought to be caused by degeneration of other neurotransmitter systems. No disease-modifying drugs are available for treatment of PD.
Issue 1618 · February 22, 2021
Comparison Table: Drugs for Parkinson's Disease (online only)

View the Comparison Table: Drugs for Parkinson's Disease

Med Lett Drugs Ther. 2021 Feb 22; 63(1618):e1-9
View the Comparison Table: Drugs for Parkinson's Disease
Issue 1615 · January 11, 2021
Opicapone (Ongentys) - A COMT Inhibitor for Parkinson's Disease

The FDA has approved opicapone ( Ongentys – Neurocrine), a peripherally-acting reversible catechol-O-methyltransferase (COMT) inhibitor, for oral use as an adjunct to carbidopa/levodopa in adults with…

Med Lett Drugs Ther. 2021 Jan 11; 63(1615):3-5
The FDA has approved opicapone ( Ongentys – Neurocrine), a peripherally-acting reversible catechol-O-methyltransferase (COMT) inhibitor, for oral use as an adjunct to carbidopa/levodopa in adults with Parkinson’s disease (PD) who experience "off" episodes. It is the third COMT inhibitor to be approved for this indication; tolcapone ( Tasmar , and generics) and entacapone ( Comtan , and generics) were approved earlier. Opicapone has been available in Europe since 2016.
Issue 1609 · October 19, 2020
Sublingual Apomorphine (Kynmobi) for Parkinson's Disease

The FDA has approved a sublingual fi lm formulation of the nonergot dopamine agonist apomorphine ( Kynmobi – Sunovion) for acute, intermittent treatment of "off" episodes in patients with Parkinson's disease…

Med Lett Drugs Ther. 2020 Oct 19; 62(1609):165-6
The FDA has approved a sublingual fi lm formulation of the nonergot dopamine agonist apomorphine ( Kynmobi – Sunovion) for acute, intermittent treatment of "off" episodes in patients with Parkinson's disease (PD). A subcutaneous formulation of apomorphine (Apokyn) has been available for years for the same indication in patients with advanced PD.
Issue 1591 · February 10, 2020
Istradefylline (Nourianz) for Parkinson's Disease

The FDA has approved istradefylline ( Nourianz — Kyowa Kirin), an oral adenosine A 2A receptor antagonist, for use as an adjunct to carbidopa/levodopa in adults with Parkinson's disease (PD) who experience…

Med Lett Drugs Ther. 2020 Feb 10; 62(1591):20-3
The FDA has approved istradefylline ( Nourianz — Kyowa Kirin), an oral adenosine A 2A receptor antagonist, for use as an adjunct to carbidopa/levodopa in adults with Parkinson's disease (PD) who experience "off" episodes. Istradefylline is the first adenosine A 2A receptor antagonist to be approved in the US; it has been available in Japan since 2013.
Issue 1572 · May 20, 2019
Inhaled Levodopa (Inbrija) for Parkinson's Disease

The FDA has approved Inbrija (Acorda), an orally inhaled dry-powder formulation of levodopa, for intermittent treatment of "off" episodes in patients with Parkinson's disease (PD) being treated with…

Med Lett Drugs Ther. 2019 May 20; 61(1572):73-4
The FDA has approved Inbrija (Acorda), an orally inhaled dry-powder formulation of levodopa, for intermittent treatment of "off" episodes in patients with Parkinson's disease (PD) being treated with carbidopa/levodopa ( Sinemet , and others).
Issue 1534 · November 20, 2017
Drugs for Parkinson's Disease

The motor symptoms of Parkinson's disease (PD) are caused primarily by degeneration of dopaminergic neurons in the substantia nigra. The nonmotor symptoms of the disease are thought to be caused by…

Med Lett Drugs Ther. 2017 Nov 20; 59(1534):187-94
The motor symptoms of Parkinson's disease (PD) are caused primarily by degeneration of dopaminergic neurons in the substantia nigra. The nonmotor symptoms of the disease are thought to be caused by degeneration of other neurotransmitter systems.
Issue 1534 · November 20, 2017
Comparison Table: Drugs for Parkinson's Disease (online only)

View the Comparison Table: Drugs for Parkinson's Disease

Med Lett Drugs Ther. 2017 Nov 20; 59(1534):e194-6
View the Comparison Table: Drugs for Parkinson's Disease
Issue 1467 · April 27, 2015
Carbidopa/Levodopa Extended-Release Capsules (Rytary)

The FDA has approved a new formulation of carbidopa/levodopa ( Rytary – Impax) in extended-release capsules for treatment of Parkinson’s disease (PD).

Med Lett Drugs Ther. 2015 Apr 27; 57(1467):59-60
The FDA has approved a new formulation of carbidopa/levodopa ( Rytary – Impax) in extended-release capsules for treatment of Parkinson’s disease (PD).